AGEN Stock Overview
A clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Agenus Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.91 |
| 52 Week High | US$42.60 |
| 52 Week Low | US$4.78 |
| Beta | 1.25 |
| 1 Month Change | 106.41% |
| 3 Month Change | -11.78% |
| 1 Year Change | -57.46% |
| 3 Year Change | -85.62% |
| 5 Year Change | -78.58% |
| Change since IPO | -99.84% |
Recent News & Updates
There's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise
May 21
Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results
May 09Recent updates
There's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise
May 21Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results
May 09Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet
Mar 29Agenus: 2024 May Finally Be The Year For A Major Turnaround
Jan 18Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet
Dec 22News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts
Nov 09A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)
Oct 04Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts
May 10VBI Vaccines, Agenus to examine VBI-1901 + balstilimab combo for glioblastoma
Oct 12Agenus New Trials Set It Up For The Long Haul
Sep 27Agenus: It's Always Tomorrow
Sep 16Agenus GAAP EPS of -$0.17, revenue of $20.93M
Aug 09Agenus: Successfully Pulled Itself Away From Disaster
Jul 04Agenus: Not Quite Enough
Apr 19Auditors Have Doubts About Agenus (NASDAQ:AGEN)
Mar 06Agenus: Making Another Effort With The FDA
Jan 25Agenus Inc.'s Imminent 1181/Bal Data Release And MiNK IPO Should Lead To Enormous Valuation Gains
Aug 25Agenus Multiple Value-Adding Events Ahead
Aug 18Party Time: Brokers Just Made Major Increases To Their Agenus Inc. (NASDAQ:AGEN) Earnings Forecasts
Aug 11FDA accepts Agenus' balstilimab BLA under "priority review" status
Jun 17Agenus/Bristol-Myers Squibb Deal Makes For A Strong Buy
May 26Shareholder Returns
| AGEN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.5% | 0.07% | -0.2% |
| 1Y | -57.5% | 6.9% | 28.2% |
Return vs Industry: AGEN underperformed the US Biotechs industry which returned 5% over the past year.
Return vs Market: AGEN underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| AGEN volatility | |
|---|---|
| AGEN Average Weekly Movement | 19.1% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: AGEN's share price has been volatile over the past 3 months.
Volatility Over Time: AGEN's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 389 | Garo Armen | www.agenusbio.com |
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant.
Agenus Inc. Fundamentals Summary
| AGEN fundamental statistics | |
|---|---|
| Market cap | US$233.51m |
| Earnings (TTM) | -US$239.61m |
| Revenue (TTM) | US$161.42m |
1.5x
P/S Ratio-1.0x
P/E RatioIs AGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AGEN income statement (TTM) | |
|---|---|
| Revenue | US$161.42m |
| Cost of Revenue | US$222.30m |
| Gross Profit | -US$60.88m |
| Other Expenses | US$178.72m |
| Earnings | -US$239.61m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.41 |
| Gross Margin | -37.72% |
| Net Profit Margin | -148.44% |
| Debt/Equity Ratio | -7.1% |
How did AGEN perform over the long term?
See historical performance and comparison